CGRP Migraine Drugs Are Generally Safe for People With Raynaud Phenomenon | Research

The takeaway

Microvascular complications from CGRP antagonist use in migraine patients with Raynaud phenomenon are uncommon (5.3%), though rare serious events including digital necrosis warrant caution.

5.3% complication rate
In migraine patients with Raynaud phenomenon, ranging from worsened symptoms to gangrene

What the researchers found

5.3% of migraine patients with Raynaud phenomenon experienced microvascular complications from CGRP antagonists, including rare but serious events like gangrene requiring digit amputation.

Why it matters

CGRP antagonists are highly effective migraine treatments, but their vasodilatory blockade poses theoretical risks for patients with vascular conditions. This study provides the first systematic safety data for this specific at-risk population.

The numbers in context

169 patients; 9 (5.3%) complications; erenumab in 5, galcanezumab in 3, fremanezumab in 1; amputation in severe cases

How the study worked

Retrospective cohort study at Mayo Clinic (May 2018 - September 2020) of 169 patients with both migraine and Raynaud phenomenon who received CGRP antagonist therapy.

Who was studied

Migraine patients with Raynaud phenomenon on CGRP antagonists (96.4% female, mean age 46)

What this study cannot tell us

Retrospective single-center design. Small number of complication cases (n=9) limits statistical power for identifying risk factors. Potential ascertainment bias at a referral center.

How to read the evidence

Retrospective cohort study from a major academic center. Moderate evidence quality limited by small complication numbers and lack of comparison group.

When this study was published

Published in 2021, covering data from the early clinical experience with CGRP antagonists (2018-2020).

The bigger picture

As CGRP-targeting drugs become first-line migraine treatments, understanding their safety in patients with comorbid vascular conditions is critical. This study fills an important knowledge gap and provides practical guidance for prescribing decisions.

Questions still open

Are there specific risk factors that predict which Raynaud patients will develop complications on CGRP antagonists?
Should Raynaud patients be screened or monitored differently when starting CGRP therapy?
Do gepants (oral CGRP antagonists) carry the same risk as monoclonal antibodies in this population?

Common questions

Is it safe to take CGRP migraine drugs if you have Raynaud's?

For most patients, yes — 94.7% in this study experienced no microvascular complications. However, 5.3% did develop problems ranging from worsened Raynaud symptoms to rare serious events. Your doctor should monitor you more closely if you have both conditions.

Why could CGRP drugs affect Raynaud phenomenon?

CGRP is a peptide that helps blood vessels dilate. Blocking it with migraine drugs can reduce this protective dilation. In people with Raynaud phenomenon, whose blood vessels already spasm excessively in fingers and toes, this loss of dilation can sometimes worsen symptoms or, rarely, cause tissue damage.

Read the original research

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.

JAMA network open, 4(4), e217934

View on PubMed ↗Publisher’s paper ↗

Citation

Breen, Ilana D; Brumfiel, Caitlin M; Patel, Meera H; Butterfield, Richard J; VanderPluym, Juliana H; Griffing, Leroy; Pittelkow, Mark R; Mangold, Aaron R. (2021). Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.. JAMA network open, 4(4), e217934. https://doi.org/10.1001/jamanetworkopen.2021.7934